Priothera develops mocravimod, a selective sphingosine-1-phosphate receptor modulator that reduces T cell egress from lymphatic tissues to enhance the graft-versus-leukemia effect while minimizing graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantation. This targeted approach aims to improve survival rates and long-term outcomes for patients with hematological malignancies, particularly acute myeloid leukemia.
Funding
$65.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Allogeneic hematopoietic cell transplantation (allo-HCT) for hematological malignancies, such as acute myeloid leukemia (AML), is often complicated by graft-versus-host disease (GvHD), which limits the curative graft-versus-leukemia (GvL) effect. Current strategies to prevent GvHD often involve broad immunosuppression, which can increase the risk of infection and relapse.
Solution
Priothera is developing mocravimod, a selective sphingosine-1-phosphate (S1P) receptor modulator, to enhance the GvL effect while minimizing GvHD in allo-HCT patients. Mocravimod works by modulating T cell trafficking, reducing the egress of T cells from lymphatic tissues. This targeted immunomodulation aims to improve survival rates and long-term outcomes for patients with hematological malignancies by decoupling the beneficial GvL effect from the detrimental effects of GvHD. The company's approach seeks to provide a safer and more effective alternative to traditional immunosuppressive regimens. Mocravimod is currently being evaluated in a Phase 3 clinical trial (MO-TRANS study).
Target Audience
The primary target audience includes patients with hematological malignancies, particularly acute myeloid leukemia (AML), undergoing allogeneic hematopoietic cell transplantation (allo-HCT), and the hematologists and oncologists who treat them.
Features
- Selective S1P receptor modulation to fine-tune T cell trafficking
- Designed to enhance graft-versus-leukemia (GvL) effect
- Aims to reduce graft-versus-host disease (GvHD)
- Non-immunosuppressive mechanism of action
- Well-characterized safety profile
- Potential for use in both allo-HCT and CAR-T cell therapy